Ipsen is a mid-sized global biopharmaceutical company focused on improving patients' lives through research and innovation in oncology, rare disease, and neuroscience. With a strong emphasis on improving patient health outcomes, Ipsen is dedicated to developing and delivering innovative pharmaceutical solutions.

FOPFDA PDUFA action date is anticipated by August 16, 2023 PARIS, FRANCE, 29 June 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the

Ipsen announces strong H1 2022 results and upgrades its full-year guidance. #FinancialResults #H1Results #Ipsen $IPN Read More: ...

Biotech Networks accelerates life science research and product development by connecting biotech professionals within and between geographic hubs using web- ...

Ipsen IPN.PA

Find contacts at this company